Block Grant R41AR055418

The National Institute of Allergy and Infectious Diseases awarded Riptide Bioscience, Inc., $1 million on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop RP557, a designed host defense peptide for topical treatment of burn wound infections. RP557 is a chemically derived antimicrobial peptide that exhibits broad activity against gram-positive and gram-negative bacteria, fungi, and biofilm-forming organisms. Preclinical studies demonstrated...

The National Institute of Biomedical Imaging and Bioengineering awarded Tissuelock LLC $314,362 on September 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop an antioxidative fiber mesh adhesive for preventing seroma and hematoma complications following abdominoplasty and large soft tissue surgeries. Seromas and hematomas occur in up to 20–30% of these procedures, leading to infection, delayed healing, repeat...

The National Institute of Diabetes and Digestive and Kidney Diseases awarded Sarxion, Inc., $1,545,942 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop SARXIONDH, a dermal extracellular matrix hydrogel for diabetic foot ulcers. The product uses extracellular matrix derived from thrombospondin 2–deficient swine, designed to promote angiogenesis, cell migration, and growth factor release in chronic wound healing. In the...

Federal Grant Award Summary Treysta Medical Technologies Inc. received a $304,984 Phase I Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) effective October 1, 2025, with completion targeted for September 30, 2026. The project is based in Gainesville, Florida and aims to develop a novel burn care therapy system designed to prevent fibrotic pathologies and reduce scarring in serious burn...

This $252,906 National Science Foundation project grant supports the development of scalable manufacturing methods for peptide amphiphile molecules by Amphix Bio Inc. The goal is to advance a safer and more affordable alternative to recombinant proteins currently used in spinal fusion surgeries. Over 500,000 such surgeries are performed annually in the U.S. to treat back and neck pain. While peptide amphiphiles show promise for reducing biological dose needs and offering consistent outcomes,...

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program will fund the development of an advanced wound care product to treat diabetic foot ulcers. The $305,000 award to Therapeutic Bandage Products, Inc. will support the creation of a patented microneedle bandage that delivers three therapeutic agents to disinfect the wound, prevent bacterial biofilm formation, and attract white blood cells to aid healing. This...

This $100,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program will support the development of an advanced wound care technology at Florida International University. Specifically, the university will create a bandage-integrated platform that provides feedback-mediated wound therapy to enable personalized care. The conformable platform is designed to non-invasively monitor multiple wound biomarkers in spatial detail and then apply targeted...

The National Heart, Lung, and Blood Institute awarded $845,268 to Laborecom Therapeutics Inc. on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) as a Phase I Small Business Innovation Research Project Grant to develop a cell-permeable peptide therapeutic that reduces myocardial reperfusion injury following ST-segment elevation myocardial infarction. Laborecom will optimize a novel therapeutic peptide targeting a motor protein uniquely expressed in endothelial...

The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of California, Los Angeles $368,156 on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop UGIGEL, a gelatin-based, self-healing bioadhesive for chronic wound treatment. The award funds research to engineer and optimize UGIGEL through a one-pot Ugi four-component reaction combining gelatin, 4-formylphenylboronic acid, gallic acid, and...

The National Institute of General Medical Sciences (part of the National Institutes of Health, Department of Health and Human Services) awarded $393,800 to the Terasaki Institute for Biomedical Innovation on September 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop immunomodulatory nanofibrous modular aerogels for chronic wound healing. The research addresses chronic wounds affecting approximately 6.5 million Americans by combining three engineered...